Clinical Trials Sponsored by ViiV Healthcare

Total 4382 results

University of Chile
ViiV Healthcare

Unknown

Proviral DNA as a Target for HIV-1 Resistance Analysis (HIV)

HIV Infections | HIV/AIDS | HIV Seropositivity | Viral Infection

Chile
Mills Clinical Research
ViiV Healthcare

Unknown

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC (STRUCTR)

Infection, Human Immunodeficiency Virus

United States
Fundacion SEIMC-GESIDA
ViiV Healthcare

Completed

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (FOSTER-C)

HCV Coinfection | Chronic HIV Infection

Spain
Orlando Immunology Center
ViiV Healthcare

Recruiting

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

HIV-1-infection

United States
University of Toronto
ViiV Healthcare

Not yet recruiting

HIV Self-Testing and Comic Intervention With Refugee Adolescents and Youth

HIV Infections | HIV/AIDS | Knowledge, Attitudes, Practice

Canada
University Hospital, Ghent
ViiV Healthcare

Recruiting

Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection (ACS)

HIV | Seroconversion, HIV

Belgium
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
Fundacion SEIMC-GESIDA
ViiV Healthcare

Completed

Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine (VOLVER)

HIV Infections

Spain
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

HIV Infections

Germany, Spain, United States, Canada, Taiwan, France, Italy, Argentina, United Kingdom, Russian Federation, Australia
Kirby Institute
Pfizer; ViiV Healthcare

Completed

Maraviroc Switch Collaborative Study (MARCH)

HIV

Spain, Australia, Ireland, Mexico, Germany, Argentina, Canada, Chile, France, Japan, Poland, Thailand, United Kingdom
University Hospital, Ghent
ViiV Healthcare

Recruiting

2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial (2DR)

HIV-1-infection

Belgium
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

HIV Infections

Germany, Taiwan, France, United States, Canada, Belgium, Australia, Netherlands, Spain, United Kingdom, Italy, Argentina, Russian Federation
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
ViiV Healthcare
MUC Research GmbH

Completed

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1 (JUNGLE)

HIV Infections

Germany
University of Nairobi
ViiV Healthcare

Completed

Second-line Switch to Dolutegravir Study (2SD)

HIV-1-infection

Kenya
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

HIV Infections

Spain, United States, Canada, Belgium, United Kingdom, Argentina
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
Pfizer; Kaiser Permanente

Completed

Kaiser Permanente HIV Cohort Study

HIV | AIDS
Tobira Therapeutics, Inc.
ViiV Healthcare

Completed

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

HIV-infection/AIDS

United States
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
Janssen Sciences Ireland UC
ViiV Healthcare

Approved for marketing

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

HIV
University of Maryland, Baltimore
ViiV Healthcare

Completed

Maraviroc Efficacy for Hepatitis C (MAVERIC)

Hepatitis C | Human Immunodeficiency Virus

United States
Rigshospitalet, Denmark
Gilead Sciences; ViiV Healthcare

Recruiting

The RESPOND Outcomes Study

HIV

Denmark, Australia, Austria, Belgium, France, Georgia, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
ViiV Healthcare
Janssen Research and Development

Active, not recruiting

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M)

HIV Infections

United States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
Saint Michael's Medical Center
ViiV Healthcare

Active, not recruiting

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) (Sound)

Human Immunodeficiency Virus

United States
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone (DOLUVOIR)

HIV-1 Infection

France
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

HIV

United Kingdom
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers

HIV

United Kingdom
St Vincent's Hospital, Sydney
ViiV Healthcare

Terminated

Efficacy of Neuro-HAART in Patients With HIV (HANDobs)

HIV

Australia
St Stephens Aids Trust
ViiV Healthcare

Unknown

Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity

HIV

United Kingdom
ViiV Healthcare
Pfizer; Copenhagen HIV Programme

Completed

EuroSIDA As An External Comparator To MOTIVATE Trials

HIV | AIDS
WV Health Right, Inc.
ViiV Healthcare

Not yet recruiting

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

HIV Infections
ViiV Healthcare
Janssen Research & Development, LLC

Recruiting

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

HIV Infections

United States
ViiV Healthcare
Janssen Research and Development

Completed

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Human Immunodeficiency Virus Type 1 (HIV-1)

Germany, Spain, United States, Italy, Canada, Argentina, Sweden
Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
Babafemi Taiwo
ViiV Healthcare

Completed

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE)

HIV Infection

United States
St Stephens Aids Trust
ViiV Healthcare

Completed

The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers (SSAT073)

HIV

United Kingdom
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

HIV-1 Infection

France
University of Liverpool
ViiV Healthcare; Makerere University

Completed

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study (DolPHIN1)

Pregnancy | HIV

Uganda, South Africa
University of Liverpool
ViiV Healthcare; Makerere University

Completed

Dolutegravir Interactions With Artemisinin-based Combination Therapies (DolACT)

HIV | Malaria

Uganda
Oregon Health and Science University
ViiV Healthcare

Recruiting

Oregon PrEP at Home Study (OR-PrEP@Home)

HIV/AIDS

United States
University Paris 7 - Denis Diderot
ViiV Healthcare

Recruiting

Patient-Reported Outcomes HIV BItherapy (PROBI)

Patient Preference | HIV/AIDS and Infections

France
University of Melbourne
The Alfred; ViiV Healthcare

Completed

Dolutegravir Impact on Residual Replication (DIORR)

HIV

Australia
Pontificia Universidad Catolica de Chile
ViiV Healthcare

Not yet recruiting

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (CABO-LA)

Quality of Life | Patient Satisfaction | Patient Preference | Acceptability of Health Care

Chile
Castagna Antonella
ViiV Healthcare

Recruiting

Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease. (PRESTIGIO)

HIV-1-infection | Multi-Antiviral Resistance

Italy
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
Chelsea and Westminster NHS Foundation Trust
ViiV Healthcare

Recruiting

Trans People Living With HIV Throughout Europe (TIME)

HIV Infections | Human Immunodeficiency Virus | Gender Identity

United Kingdom, Italy
ViiV Healthcare
GlaxoSmithKline; Pharmaceutical Product Development (PPD), Inc

Completed

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

HIV Infections

United States

Clinical Trials Sponsored by ViiV Healthcare

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations